Dosage
Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns
Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor
Lilly Makes All Zepbound Doses Available via Direct Pay Program
Zepbound; Eli Lilly; direct pay; LillyDirect; tirzepatide; obesity medication; dose availability; pharmacy platform
Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial
Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment
Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides
MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1
Lexicon stumbles on second batch of mixed results for pain drug
Dosage, lexicon, Statistical Significance
Eli Lilly makes Zepbound vials cheaper for self-paying patients
self-paying, Eli, Eli Lilly, Prices, Monthly (qualifier value), Dosage, 7.5 mg, 10 mg
Lilly lowers price of Zepbound vials, launches new doses
Eli Lilly, Dosage, Prices, Affordability, Obesity
Jasper Therapeutics Escalates Dose in Hives Trial Following Rapid Complete Responses
Jasper Therapeutics, briquilimab, chronic inducible urticaria, hives, dose escalation, clinical trial, SPOTLIGHT study
Biogen Announces Positive Results from Higher Dose Spinraza Study in Spinal Muscular Atrophy Patients
Biogen, Spinraza, spinal muscular atrophy, SMA, higher dose, clinical trial, DEVOTE study
Minimal Weight Reduction Observed with Low Doses of New Zealand’s GLP-1/GLP-2 Agonist
New Zealand, GLP-1/GLP-2 agonist, weight reduction, lowest doses, minimal effect.